Risdiplam Defies SMA ‘Natural History’ in Type 1 Infants, FIREFISH Data Show
Roche’s experimental oral treatment risdiplam can safely and effectively halt disease progression in infants with type 1 spinal muscular atrophy (SMA) under 7 months of age, according to top-line data from Part 2 of the FIREFISH trial. After one year of treatment, most of these 41 babies…